Laboratorios Richmond S.A.C.I.F
Buy or Sell?

I guess you are interested in Laboratorios Richmond S.A.C.I.F. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Laboratorios Richmond S.A.C.I.F Daily Candlestick Chart

Let's start. I'm going to help you getting a better view of Laboratorios Richmond S.A.C.I.F. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Company's Financial Health
A deep dive into the books. How are the numbers doing? Is Laboratorios Richmond S.A.C.I.F even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
Market Valuation
Finally, you now have an insight of how Laboratorios Richmond S.A.C.I.F is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Laboratorios Richmond S.A.C.I.F. The closing price on 2022-06-24 was ARS238.00 per share. Is the company over- or underpriced?
Key Performance Indicators
A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.

1.1. Profitability of Laboratorios Richmond S.A.C.I.F.

An important factor of a company's health is the profitability.

1.1.1. Net Profit Margin of Laboratorios Richmond S.A.C.I.F.

One of the most important indicator to determine the financial health of a company is the Net Profit Margin. What is the net profit from the generated revenue? A healthy Net Profit Margin is higher than 10%.

Period	Laboratorios Richmond S.A.C.I.F	Drug Manufacturers-Specialty & Generic (mean)	Drug Manufacturers-Specialty & Generic (average)
MRQ	8.7%	2.2%	-423.9%
TTM	0.9%	1.5%	-43,400.5%
YOY	6.3%	2.4%	-6,664.9%
5Y	1.2%	0.6%	-11,269.3%
10Y	2.4%	1.3%	-7,239.8%

Let's take a look of the Net Profit Margin trends of Laboratorios Richmond S.A.C.I.F:

The MRQ is 8.7%. Neutral. Compare to industry.
The TTM is 0.9%. Very low, is it enough? Compare to industry. -1
The TTM is 0.9%. Compared to the MRQ, the short term is trending up. +1
The YOY is 6.3%. Compared to the TTM, the mid term is trending down. -1
The 5Y is 1.2%. Compared to the TTM, the 5Y term is trending down. -1
The 10Y is 2.4%. Compared to the 5Y term, the 10Y term is trending down. -1

Let's compare the company's Net Profit Margin with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:

The MRQ average (mean) in the Drug Manufacturers-Specialty & Generic industry is 2.2%. The company's MRQ (8.7%) is outperforming the industry with 6.5%. +1
The TTM average (mean) in the Drug Manufacturers-Specialty & Generic industry is 1.5%. The company's TTM (0.9%) is underperforming the industry with -0.6%. -1

1.1.2. Return On Assets of Laboratorios Richmond S.A.C.I.F.

A healthy Return On Assets is above 5%.

Period	Laboratorios Richmond S.A.C.I.F	Drug Manufacturers-Specialty & Generic (mean)	Drug Manufacturers-Specialty & Generic (average)
MRQ	2.7%	0.4%	-31.1%
TTM	0.5%	0.2%	-5,075.2%
YOY	1.6%	0.2%	-1,456.2%
5Y	0.4%	0.1%	-1,385.0%
10Y	0.8%	0.3%	-870.0%

Let's take a look of the Return On Assets trends of Laboratorios Richmond S.A.C.I.F:

The MRQ is 2.7%. Neutral. Compare to industry.
The TTM is 0.5%. Bad. -1
The TTM is 0.5%. Compared to the MRQ, the short term is trending up. +1
The YOY is 1.6%. Compared to the TTM, the mid term is trending down. -1
The 5Y is 0.4%. Compared to the TTM, the 5Y term is trending up. +1
The 10Y is 0.8%. Compared to the 5Y term, the 10Y term is trending down. -1

Let's compare the company's Return On Assets with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:

The MRQ average (mean) in the Drug Manufacturers-Specialty & Generic industry is 0.4%. The company's MRQ (2.7%) is outperforming the industry with 2.3%. +1
The TTM average (mean) in the Drug Manufacturers-Specialty & Generic industry is 0.2%. The company's TTM (0.5%) is outperforming the industry with 0.3%. +1

1.1.3. Return On Equity of Laboratorios Richmond S.A.C.I.F.

A healthy Return On Equity is above 15%.

Period	Laboratorios Richmond S.A.C.I.F	Drug Manufacturers-Specialty & Generic (mean)	Drug Manufacturers-Specialty & Generic (average)
MRQ	13.2%	1.2%	-10.9%
TTM	2.7%	0.8%	-20,263.5%
YOY	3.9%	0.7%	-38.9%
5Y	1.7%	0.3%	-3,852.7%
10Y	3.4%	0.6%	-1,919.9%

Let's take a look of the Return On Equity trends of Laboratorios Richmond S.A.C.I.F:

The MRQ is 13.2%. Neutral. Compare to industry.
The TTM is 2.7%. Bad. -1
The TTM is 2.7%. Compared to the MRQ, the short term is trending up. +1
The YOY is 3.9%. Compared to the TTM, the mid term is trending down. -1
The 5Y is 1.7%. Compared to the TTM, the 5Y term is trending up. +1
The 10Y is 3.4%. Compared to the 5Y term, the 10Y term is trending down. -1

Let's compare the company's Return On Equity with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:

The MRQ average (mean) in the Drug Manufacturers-Specialty & Generic industry is 1.2%. The company's MRQ (13.2%) is outperforming the industry with 12.0%. +1
The TTM average (mean) in the Drug Manufacturers-Specialty & Generic industry is 0.8%. The company's TTM (2.7%) is outperforming the industry with 1.9%. +1

1.2. Operating Efficiency of Laboratorios Richmond S.A.C.I.F.

1.2.1. Operating Margin of Laboratorios Richmond S.A.C.I.F.

A healthy Operating Margin is above 15%.

Period	Laboratorios Richmond S.A.C.I.F	Drug Manufacturers-Specialty & Generic (mean)	Drug Manufacturers-Specialty & Generic (average)
MRQ	-	4.9%	-326.8%
TTM	13.7%	2.8%	-37,528.8%
YOY	21.0%	4.1%	8,834.9%
5Y	8.4%	3.1%	-4,596.1%
10Y	4.7%	2.0%	-1,187.8%

Let's take a look of the Operating Margin trends of Laboratorios Richmond S.A.C.I.F:

The MRQ is 0.0%. The data is not here.
The YOY is 21.0%. Compared to the TTM, the mid term is trending down. -1
The 5Y is 8.4%. Compared to the TTM, the 5Y term is trending up. +1
The 10Y is 4.7%. Compared to the 5Y term, the 10Y term is trending up. +1

Let's compare the company's Operating Margin with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:

The MRQ average (mean) in the Drug Manufacturers-Specialty & Generic industry is 4.9%. The company's MRQ (0.0%) is underperforming the industry with -4.9%. -1
The TTM average (mean) in the Drug Manufacturers-Specialty & Generic industry is 2.8%. The company's TTM (13.7%) is outperforming the industry with 10.9%. +1

1.2.2. Operating Ratio of Laboratorios Richmond S.A.C.I.F.

A healthy Operating Ratio is below 1.

Period	Laboratorios Richmond S.A.C.I.F	Drug Manufacturers-Specialty & Generic (mean)	Drug Manufacturers-Specialty & Generic (average)
MRQ	1.556	1.382	3.673
TTM	1.477	1.361	1,600.776
YOY	1.267	1.373	-87.241
5Y	1.074	1.318	277.684
10Y	0.809	1.147	130.843

Let's take a look of the Operating Ratio trends of Laboratorios Richmond S.A.C.I.F:

The MRQ is 1.556. Very good. +2
The TTM is 1.477. Very good. +2
The TTM is 1.477. Compared to the MRQ, the short term is trending up. -1
The YOY is 1.267. Compared to the TTM, the mid term is trending up. -1
The 5Y is 1.074. Compared to the TTM, the 5Y term is trending up. -1
The 10Y is 0.809. Compared to the 5Y term, the 10Y term is trending up. -1

Let's compare the company's Operating Ratio with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:

The MRQ average (mean) in the Drug Manufacturers-Specialty & Generic industry is 1.382. The company's MRQ (1.556) is underperforming the industry with 0.174. -1
The TTM average (mean) in the Drug Manufacturers-Specialty & Generic industry is 1.361. The company's TTM (1.477) is underperforming the industry with 0.116. -1

1.3. Liquidity of Laboratorios Richmond S.A.C.I.F.

1.3.1. Current Ratio of Laboratorios Richmond S.A.C.I.F.

A healthy Current Ratio is above 1.

Period	Laboratorios Richmond S.A.C.I.F	Drug Manufacturers-Specialty & Generic (mean)	Drug Manufacturers-Specialty & Generic (average)
MRQ	1.655	2.011	3.916
TTM	1.382	2.049	3.587
YOY	1.346	2.093	3.306
5Y	0.899	2.121	5.082
10Y	0.499	1.843	4.686

Let's take a look of the Current Ratio trends of Laboratorios Richmond S.A.C.I.F:

The MRQ is 1.655. Good. +1
The TTM is 1.382. Neutral. Compare to industry.
The TTM is 1.382. Compared to the MRQ, the short term is trending up. +1
The YOY is 1.346. Compared to the TTM, the mid term is trending up. +1
The 5Y is 0.899. Compared to the TTM, the 5Y term is trending up. +1
The 10Y is 0.499. Compared to the 5Y term, the 10Y term is trending up. +1

Let's compare the company's Current Ratio with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:

The MRQ average (mean) in the Drug Manufacturers-Specialty & Generic industry is 2.011. The company's MRQ (1.655) is underperforming the industry with -0.356. -1
The TTM average (mean) in the Drug Manufacturers-Specialty & Generic industry is 2.049. The company's TTM (1.382) is underperforming the industry with -0.667. -1

1.3.2. Quick Ratio of Laboratorios Richmond S.A.C.I.F.

A healthy Quick Ratio is above 1.

Period	Laboratorios Richmond S.A.C.I.F	Drug Manufacturers-Specialty & Generic (mean)	Drug Manufacturers-Specialty & Generic (average)
MRQ	0.668	0.731	2.207
TTM	0.523	0.834	2.206
YOY	0.745	0.804	1.933
5Y	0.647	0.835	1.881
10Y	0.691	0.812	1.806

Let's take a look of the Quick Ratio trends of Laboratorios Richmond S.A.C.I.F:

The MRQ is 0.668. Warning. Indication that company may not be able to fully pay off its current liabilities in the short term. -1
The TTM is 0.523. Warning. Indication that company may not be able to fully pay off its current liabilities in the short term. -1
The TTM is 0.523. Compared to the MRQ, the short term is trending up. +1
The YOY is 0.745. Compared to the TTM, the mid term is trending down. -1
The 5Y is 0.647. Compared to the TTM, the 5Y term is trending down. -1
The 10Y is 0.691. Compared to the 5Y term, the 10Y term is trending down. -1

Let's compare the company's Quick Ratio with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:

The MRQ average (mean) in the Drug Manufacturers-Specialty & Generic industry is 0.731. The company's MRQ (0.668) is underperforming the industry with -0.063. -1
The TTM average (mean) in the Drug Manufacturers-Specialty & Generic industry is 0.834. The company's TTM (0.523) is underperforming the industry with -0.311. -1

1.4. Solvency of Laboratorios Richmond S.A.C.I.F.

1.4.1. Total-Debt-to-Total-Assets Ratio of Laboratorios Richmond S.A.C.I.F.

A healthy Total-Debt-to-Total-Assets Ratio is below 1.

Period	Laboratorios Richmond S.A.C.I.F	Drug Manufacturers-Specialty & Generic (mean)	Drug Manufacturers-Specialty & Generic (average)
MRQ	0.791	0.412	5.044
TTM	0.718	0.411	5.946
YOY	0.591	0.396	24.438
5Y	0.649	0.396	9.475
10Y	0.698	0.400	9.057

Let's take a look of the Total-Debt-to-Total-Assets Ratio trends of Laboratorios Richmond S.A.C.I.F:

The MRQ is 0.791. Tight, but oke.
The TTM is 0.718. Healty. +1
The TTM is 0.718. Compared to the MRQ, the short term is trending up. -1
The YOY is 0.591. Compared to the TTM, the mid term is trending up. -1
The 5Y is 0.649. Compared to the TTM, the 5Y term is trending up. -1
The 10Y is 0.698. Compared to the 5Y term, the 10Y term is trending down. +1

Let's compare the company's Total-Debt-to-Total-Assets Ratio with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:

The MRQ average (mean) in the Drug Manufacturers-Specialty & Generic industry is 0.412. The company's MRQ (0.791) is underperforming the industry with 0.379. -1
The TTM average (mean) in the Drug Manufacturers-Specialty & Generic industry is 0.411. The company's TTM (0.718) is underperforming the industry with 0.307. -1

1.4.2. Debt-To-Equity Ratio of Laboratorios Richmond S.A.C.I.F.

A healthy Debt-To-Equity Ratio is below 2.

Period	Laboratorios Richmond S.A.C.I.F	Drug Manufacturers-Specialty & Generic (mean)	Drug Manufacturers-Specialty & Generic (average)
MRQ	3.838	0.625	2.583
TTM	3.009	0.660	2.312
YOY	1.475	0.624	2.751
5Y	2.148	0.664	1.949
10Y	2.703	0.688	1.750

Let's take a look of the Debt-To-Equity Ratio trends of Laboratorios Richmond S.A.C.I.F:

The MRQ is 3.838. Bad. To much debt compared to equity. -1
The TTM is 3.009. Bad. To much debt compared to equity. -1
The TTM is 3.009. Compared to the MRQ, the short term is trending up. -1
The YOY is 1.475. Compared to the TTM, the mid term is trending up. -1
The 5Y is 2.148. Compared to the TTM, the 5Y term is trending up. -1
The 10Y is 2.703. Compared to the 5Y term, the 10Y term is trending down. +1

Let's compare the company's Debt-To-Equity Ratio with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:

The MRQ average (mean) in the Drug Manufacturers-Specialty & Generic industry is 0.625. The company's MRQ (3.838) is underperforming the industry with 3.213. -1
The TTM average (mean) in the Drug Manufacturers-Specialty & Generic industry is 0.660. The company's TTM (3.009) is underperforming the industry with 2.349. -1

2. Market Valuation of Laboratorios Richmond S.A.C.I.F.

2.1. Price-to-Earnings Ratio of Laboratorios Richmond S.A.C.I.F.

A Price-to-Earnings Ratio above 15 may indicate an overpriced stock. However this is very hard to determine. Best way is to compare the PE Ratio with the industry average.

Period	Laboratorios Richmond S.A.C.I.F	Drug Manufacturers-Specialty & Generic (mean)	Drug Manufacturers-Specialty & Generic (average)
EOD	-182.704	0.410	0.584
MRQ	-170.421	1.141	-3.303
TTM	0.101	1.001	17.337
YOY	32.273	3.073	-83.308
5Y	1.912	5.909	-127.348
10Y	1.062	7.016	-147.432

Let's take a look of the Price-to-Earnings Ratio trends of Laboratorios Richmond S.A.C.I.F:

The EOD is -182.704. Company is losing money. -2
The MRQ is -170.421. Company is losing money. -2
The TTM is 0.101. Very good. +2
The TTM is 0.101. Compared to the MRQ, the short term is trending down. +1
The YOY is 32.273. Compared to the TTM, the mid term is trending down. +1
The 5Y is 1.912. Compared to the TTM, the 5Y term is trending down. +1
The 10Y is 1.062. Compared to the 5Y term, the 10Y term is trending up. -1

Let's compare the company's Price-to-Earnings Ratio with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:

The MRQ average (mean) in the Drug Manufacturers-Specialty & Generic industry is 1.141. The company's MRQ (-170.421) is outperforming the industry with -171.562. +1
The TTM average (mean) in the Drug Manufacturers-Specialty & Generic industry is 1.001. The company's TTM (0.101) is outperforming the industry with -0.900. +1

2.2. Price/Earnings-to-Growth Ratio of Laboratorios Richmond S.A.C.I.F.

Period	Laboratorios Richmond S.A.C.I.F	Drug Manufacturers-Specialty & Generic (mean)	Drug Manufacturers-Specialty & Generic (average)
MRQ	787.761	1.089	-224.992
TTM	241.981	0.041	110.620
YOY	-8.345	3.351	12,755.229
5Y	116.818	7.424	17,111.564
10Y	116.818	7.758	11,093.204

Let's take a look of the Price/Earnings-to-Growth Ratio trends of Laboratorios Richmond S.A.C.I.F:

The MRQ is 787.761. Seems overpriced? -1
The TTM is 241.981. Seems overpriced? -1
The TTM is 241.981. Compared to the MRQ, the short term is trending up. -1
The YOY is -8.345. Compared to the TTM, the mid term is trending up. -1
The 5Y is 116.818. Compared to the TTM, the 5Y term is trending up. -1
The 10Y is 116.818. Compared to the 5Y term, the 10Y term is not trending.

Let's compare the company's Price/Earnings-to-Growth Ratio with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:

The MRQ average (mean) in the Drug Manufacturers-Specialty & Generic industry is 1.089. The company's MRQ (787.761) is underperforming the industry with 786.672. -1
The TTM average (mean) in the Drug Manufacturers-Specialty & Generic industry is 0.041. The company's TTM (241.981) is underperforming the industry with 241.940. -1

2.3. Price-to-Book Ratio of Laboratorios Richmond S.A.C.I.F.

A healthy Price-to-Book Ratio is below 3.

Period	Laboratorios Richmond S.A.C.I.F	Drug Manufacturers-Specialty & Generic (mean)	Drug Manufacturers-Specialty & Generic (average)
EOD	3.575	1.637	58.918
MRQ	3.335	1.926	162.075
TTM	4.086	2.197	51.679
YOY	3.299	2.274	299.576
5Y	2.153	2.034	79.132
10Y	1.196	1.573	77.620

Let's take a look of the Price-to-Book Ratio trends of Laboratorios Richmond S.A.C.I.F:

The EOD is 3.575. Neutral. Compare to industry.
The MRQ is 3.335. Neutral. Compare to industry.
The TTM is 4.086. Neutral. Compare to industry.
The TTM is 4.086. Compared to the MRQ, the short term is trending down. +1
The YOY is 3.299. Compared to the TTM, the mid term is trending up. -1
The 5Y is 2.153. Compared to the TTM, the 5Y term is trending up. -1
The 10Y is 1.196. Compared to the 5Y term, the 10Y term is trending up. -1

Let's compare the company's Price-to-Book Ratio with the average (mean) in the Drug Manufacturers-Specialty & Generic industry:

The MRQ average (mean) in the Drug Manufacturers-Specialty & Generic industry is 1.926. The company's MRQ (3.335) is underperforming the industry with 1.409. -1
The TTM average (mean) in the Drug Manufacturers-Specialty & Generic industry is 2.197. The company's TTM (4.086) is underperforming the industry with 1.889. -1

	End of day	+/-	Most Recent Quarter	Trailing 12 Months	+/-	Year-Over-Year	+/-	5 Year	+/-	10 Year	+/-
Book Value Per Share	-	-	66.570	54.255	+23%	33.132	+101%	21.125	+215%	11.736	+467%
Current Ratio	-	-	1.655	1.382	+20%	1.346	+23%	0.899	+84%	0.499	+231%
Debt To Asset Ratio	-	-	0.791	0.718	+10%	0.591	+34%	0.649	+22%	0.698	+13%
Debt To Equity Ratio	-	-	3.838	3.009	+28%	1.475	+160%	2.148	+79%	2.703	+42%
Eps	-	-	-	-0.326	0%	1.505	-100%	0.308	-100%	0.171	-100%
Gross Profit Margin	-	-	1.000	1.000	0%	1.000	0%	0.950	+5%	0.833	+20%
Net Profit Margin	-	-	0.087	0.009	+821%	0.063	+39%	0.012	+608%	0.024	+257%
Operating Margin	-	-	-	0.137	-100%	0.210	-100%	0.084	-100%	0.047	-100%
Operating Ratio	-	-	1.556	1.477	+5%	1.267	+23%	1.074	+45%	0.809	+92%
Pb Ratio	3.575	+7%	3.335	4.086	-18%	3.299	+1%	2.153	+55%	1.196	+179%
Pe Ratio	-182.704	-7%	-170.421	0.101	-168964%	32.273	-628%	1.912	-9015%	1.062	-16146%
Peg Ratio	-	-	787.761	241.981	+226%	-8.345	+101%	116.818	+574%	116.818	+574%
Price Per Share	238.000	+7%	222.000	219.500	+1%	107.438	+107%	86.063	+158%	47.813	+364%
Quick Ratio	-	-	0.668	0.523	+28%	0.745	-10%	0.647	+3%	0.691	-3%
Return On Assets	-	-	0.027	0.005	+438%	0.016	+71%	0.004	+540%	0.008	+246%
Return On Equity	-	-	0.132	0.027	+389%	0.039	+234%	0.017	+687%	0.034	+284%

Indicator	Condition	Value
PE Ratio (EOD)	Between	0-15	-182.704
PB Ratio (EOD)	Between	0-1	3.575
Net Profit Margin (MRQ)	Greater than	0	0.087
Operating Margin (MRQ)	Greater than	0	0.000
Quick Ratio (MRQ)	Greater than	1	0.668
Current Ratio (MRQ)	Greater than	1	1.655
Debt Ratio (MRQ)	Less than	1	0.791
DE Ratio (MRQ)	Less than	1	3.838
ROE (MRQ)	Greater than	0.15	0.132
ROA (MRQ)	Greater than	0.05	0.027
Total	3/10 (30.0%)

Indicator	Condition	Value
Rsi	Greater than	50	49.092
Ma 20	Greater than	Ma 50	238.613
Ma 50	Greater than	Ma 100	237.075
Ma 100	Greater than	Ma 200	241.140
Open	Greater than	Close	235.000
Total	2/5 (40.0%)

Total Assets	25,693,158
Total Liabilities	20,317,526
Total Stockholder Equity	5,293,621

	As reported
Total Liabilities	20,317,526
Total Stockholder Equity	+ 5,293,621
Total Assets	= 25,693,158

Total Assets	25,693,158
Total Current Assets	15,434,862
Long-term Assets	15,434,862

Cash And Cash Equivalents	4,666,788
Short-term Investments	2,693,158
Net Receivables	3,532,618
Inventory	3,824,574
Total Current Assets (as reported)	15,434,862
Total Current Assets (calculated)	14,717,138
+/-	717,724

Goodwill	531,171
Intangible Assets	1,462,932
Long-term Assets (as reported)	10,258,296
Long-term Assets (calculated)	1,994,102
+/-	8,264,193

Total Current Liabilities	9,326,184
Long-term Liabilities	10,991,342
Total Stockholder Equity	5,293,621

Short Long Term Debt	1,788,036
Accounts payable	5,724,387
Other Current Liabilities	30,000
Total Current Liabilities (as reported)	9,326,184
Total Current Liabilities (calculated)	7,542,424
+/-	1,783,760

Long term Debt	1,187,600
Capital Lease Obligations Min Short Term Debt	146,125
Long-term Liabilities Other	12,302
Long-term Liabilities (as reported)	10,991,342
Long-term Liabilities (calculated)	1,346,028
+/-	9,645,315

Retained Earnings	591,464
Total Stockholder Equity (as reported)	5,293,621
Total Stockholder Equity (calculated)	591,464
+/-	4,702,157

Trend

2021-12-31

2021-09-30

2021-06-30

2021-03-31

2020-12-31

2020-09-30

2020-06-30

2020-03-31

2019-12-31

2019-09-30

2019-06-30

2019-03-31

2018-12-31

2018-09-30

2018-06-30

2018-03-31

2017-12-31

2017-09-30

2017-06-30

2017-03-31

2016-12-31

2016-09-30

2016-06-30

2016-03-31

2015-12-31

2015-09-30

2015-06-30

2015-03-31

2014-12-31

2014-09-30

2014-06-30

2014-03-31

2013-12-31

2013-09-30

2013-06-30

2013-03-31

2012-12-31

2011-12-31

2010-12-31

2009-12-31

2008-12-31

2008-09-30

2007-09-30

2006-09-30

> Total Assets

56,356
77,583
100,634
107,007
127,840
135,779
159,025
270,955
276,743
276,743
290,686
287,372
315,091
323,549
357,608
385,658
387,299
391,705
400,815
532,834
556,555
640,283
724,917
861,132
726,253
779,149
912,391
1,552,641
1,637,185
1,821,701
2,402,981
2,705,186
2,805,766
2,948,371
3,807,181
5,134,618
5,260,627
5,845,090
6,986,402
8,133,335
9,254,840
12,165,119
24,167,525
25,693,158

25,693,158

24,167,525

12,165,119

9,254,840

8,133,335

6,986,402

5,845,090

5,260,627

5,134,618

3,807,181

2,948,371

2,805,766

2,705,186

2,402,981

1,821,701

1,637,185

1,552,641

912,391

779,149

726,253

861,132

724,917

640,283

556,555

532,834

400,815

391,705

387,299

385,658

357,608

323,549

315,091

287,372

290,686

276,743

270,955

159,025

135,779

127,840

107,007

100,634

77,583

56,356

> Total Current Assets

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,967,306
1,914,169
1,894,278
2,571,194
3,287,659
3,263,874
3,591,461
4,519,380
5,371,511
5,406,240
7,750,533
10,771,693
15,434,862

15,434,862

10,771,693

7,750,533

5,406,240

5,371,511

4,519,380

3,591,461

3,263,874

3,287,659

2,571,194

1,894,278

1,914,169

1,967,306

Cash And Cash Equivalents

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
501,119
347,465
258,089
350,686
217,146
310,788
500,976
315,168
493,831
516,623
404,284
1,597,793
4,666,788

4,666,788

1,597,793

404,284

516,623

493,831

315,168

500,976

310,788

217,146

350,686

258,089

347,465

501,119

Short-term Investments

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
481
799
1,148
3,668
1,720
1,188
1,085
357,776
345,707
347,005
532,356
85,949
2,693,158

2,693,158

85,949

532,356

347,005

345,707

357,776

1,085

1,188

1,720

3,668

1,148

799

481

Net Receivables

16,278
24,723
24,876
27,233
31,007
35,816
46,019
96,359
105,744
105,744
114,664
111,643
126,968
134,815
156,568
192,546
180,550
185,857
173,047
267,087
262,666
267,879
311,128
498,253
338,047
329,962
406,844
512,300
653,201
690,781
885,401
785,003
616,057
678,506
958,190
1,959,409
1,852,293
1,672,216
2,159,626
2,936,487
1,925,213
2,691,864
2,496,087
3,532,618

3,532,618

2,496,087

2,691,864

1,925,213

2,936,487

2,159,626

1,672,216

1,852,293

1,959,409

958,190

678,506

616,057

785,003

885,401

690,781

653,201

512,300

406,844

329,962

338,047

498,253

311,128

267,879

262,666

267,087

173,047

185,857

180,550

192,546

156,568

134,815

126,968

111,643

114,664

105,744

96,359

46,019

35,816

31,007

27,233

24,876

24,723

16,278

Other Current Assets

918
888
15,252
16,553
13,310
953
606
498
0
0
0
0
0
0
0
0
0
0
0
4,546
18,756
9,874
14,311
14,666
11,873
12,404
24,376
12,994
28,038
32,646
20,857
150,080
180,388
124,871
172,835
178,477
197,338
248,894
421,935
287,748
546,618
1,191,245
372,305
0

372,305

1,191,245

546,618

287,748

421,935

248,894

197,338

178,477

172,835

124,871

180,388

150,080

20,857

32,646

28,038

12,994

24,376

12,404

11,873

14,666

14,311

9,874

18,756

4,546

498

606

953

13,310

16,553

15,252

888

918

> Long-term Assets

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
891,597
1,054,093
1,235,987
1,846,959
1,996,753
2,253,630
2,467,021
3,168,386
3,848,600
4,414,586
13,395,832
10,258,296

10,258,296

13,395,832

4,414,586

3,848,600

3,168,386

2,467,021

2,253,630

1,996,753

1,846,959

1,235,987

1,054,093

891,597

Property Plant Equipment

13,126
20,344
22,083
22,179
22,918
37,995
44,800
52,499
0
0
0
52,549
52,428
0
54,516
54,525
53,702
54,699
53,642
55,316
55,560
55,322
56,996
58,306
67,184
70,593
71,867
91,973
91,649
96,152
198,977
383,959
472,937
569,658
671,096
1,196,276
1,250,129
1,347,306
1,429,438
2,015,013
2,337,935
2,725,498
3,046,123
0

3,046,123

2,725,498

2,337,935

2,015,013

1,429,438

1,347,306

1,250,129

1,196,276

671,096

569,658

472,937

383,959

198,977

96,152

91,649

91,973

71,867

70,593

67,184

58,306

56,996

55,322

55,560

55,316

53,642

54,699

53,702

54,525

54,516

52,428

52,549

52,499

44,800

37,995

22,918

22,179

22,083

20,344

13,126

Goodwill

0
0
0
0
0
0
0
40,438
0
0
0
31,420
30,973
0
30,079
29,632
29,184
28,737
28,290
31,420
31,420
31,420
31,420
31,420
31,420
31,420
39,783
32,339
32,248
32,609
33,121
143,669
178,636
193,533
221,859
245,929
287,113
304,512
328,063
300,277
409,657
449,661
486,155
531,171

531,171

486,155

449,661

409,657

300,277

328,063

304,512

287,113

245,929

221,859

193,533

178,636

143,669

33,121

32,609

32,248

32,339

39,783

31,420

28,290

28,737

29,184

29,632

30,079

30,973

31,420

40,438

Long Term Investments

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,692
4,101
5,355
5,500
4,218
0
0
0
0
0
0
0
0

4,218

5,500

5,355

4,101

11,692

Intangible Assets

311
457
1,622
691
679
543
147
40,625
5,964
5,964
6,174
31,420
30,973
6,788
30,079
29,632
29,184
28,737
28,771
31,420
31,420
31,420
31,420
31,420
31,420
31,420
39,783
32,339
32,376
32,821
33,913
3,200
188,206
240,895
288,322
335,738
379,915
421,531
508,649
623,643
804,240
975,114
1,128,651
1,462,932

1,462,932

1,128,651

975,114

804,240

623,643

508,649

421,531

379,915

335,738

288,322

240,895

188,206

3,200

33,913

32,821

32,376

32,339

39,783

31,420

28,771

28,737

29,184

29,632

30,079

6,788

30,973

31,420

6,174

5,964

40,625

147

543

679

691

1,622

457

311

Long-term Assets Other

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
891,597
1,054,093
1,235,987
0
0
0
0
0
0
0
0
0

1,235,987

1,054,093

891,597

> Total Liabilities

48,610
64,334
71,342
68,621
74,108
90,962
108,921
178,942
185,468
185,468
207,433
196,336
235,531
243,608
274,160
292,642
299,363
300,866
303,726
436,712
460,578
540,743
605,060
671,672
549,419
625,695
715,969
864,588
911,607
1,130,640
1,616,125
1,594,256
1,669,514
1,731,410
2,369,968
3,034,658
3,051,279
3,443,970
4,275,481
4,752,830
5,500,623
8,099,865
19,838,051
20,317,526

20,317,526

19,838,051

8,099,865

5,500,623

4,752,830

4,275,481

3,443,970

3,051,279

3,034,658

2,369,968

1,731,410

1,669,514

1,594,256

1,616,125

1,130,640

911,607

864,588

715,969

625,695

549,419

671,672

605,060

540,743

460,578

436,712

303,726

300,866

299,363

292,642

274,160

243,608

235,531

196,336

207,433

185,468

178,942

108,921

90,962

74,108

68,621

71,342

64,334

48,610

> Total Current Liabilities

36,242
32,065
51,411
48,157
50,443
49,927
70,886
132,790
144,643
144,643
164,239
153,556
182,401
186,583
218,576
239,846
243,496
240,821
222,613
337,703
354,829
390,143
455,045
546,952
425,365
516,202
634,249
748,417
780,462
954,980
1,327,483
1,250,101
1,267,508
1,380,095
2,005,622
2,475,950
2,480,757
2,820,832
3,522,630
3,550,319
3,695,913
5,913,989
9,805,072
9,326,184

9,326,184

9,805,072

5,913,989

3,695,913

3,550,319

3,522,630

2,820,832

2,480,757

2,475,950

2,005,622

1,380,095

1,267,508

1,250,101

1,327,483

954,980

780,462

748,417

634,249

516,202

425,365

546,952

455,045

390,143

354,829

337,703

222,613

240,821

243,496

239,846

218,576

186,583

182,401

153,556

164,239

144,643

132,790

70,886

49,927

50,443

48,157

51,411

32,065

36,242

Short-term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
302,330
341,545
340,886
449,337
346,659
0
0
0
0
0
0
0
0

346,659

449,337

340,886

341,545

302,330

Short Long Term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
302,330
341,545
340,886
449,337
346,659
325,998
566,163
987,993
659,873
632,373
1,871,833
2,090,837
1,788,036

1,788,036

2,090,837

1,871,833

632,373

659,873

987,993

566,163

325,998

346,659

449,337

340,886

341,545

302,330

Accounts payable

33,502
27,105
43,601
40,415
36,735
25,200
36,272
72,066
63,494
63,494
68,286
55,509
82,352
79,388
100,744
102,671
116,583
109,532
105,153
161,772
177,376
189,468
195,173
225,076
190,964
280,531
365,272
375,389
373,387
530,682
833,245
857,549
854,992
967,806
1,428,534
1,861,857
1,905,383
2,028,514
2,226,285
2,360,382
2,721,935
3,739,832
6,263,583
5,724,387

5,724,387

6,263,583

3,739,832

2,721,935

2,360,382

2,226,285

2,028,514

1,905,383

1,861,857

1,428,534

967,806

854,992

857,549

833,245

530,682

373,387

375,389

365,272

280,531

190,964

225,076

195,173

189,468

177,376

161,772

105,153

109,532

116,583

102,671

100,744

79,388

82,352

55,509

68,286

63,494

72,066

36,272

25,200

36,735

40,415

43,601

27,105

33,502

Other Current Liabilities

540
2,308
3,001
2,862
2,442
4,252
7,325
15,221
20,912
20,912
17,560
11,919
13,022
14,132
15,077
19,240
18,811
24,886
20,877
36,280
51,298
52,763
59,489
114,519
63,502
78,660
68,825
100,418
102,432
70,939
119,724
22,193
8
8,504
11,529
51,563
78,576
108,638
147,153
159,442
73,729
83,902
92,093
30,000

30,000

92,093

83,902

73,729

159,442

147,153

108,638

78,576

51,563

11,529

8,504

22,193

119,724

70,939

102,432

100,418

68,825

78,660

63,502

114,519

59,489

52,763

51,298

36,280

20,877

24,886

18,811

19,240

15,077

14,132

13,022

11,919

17,560

20,912

15,221

7,325

4,252

2,442

2,862

3,001

2,308

540

> Long-term Liabilities

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
402,006
351,315
364,345
558,708
570,522
623,138
752,851
1,486,170
1,804,710
2,185,876
10,032,979
10,991,342

10,991,342

10,032,979

2,185,876

1,804,710

1,486,170

752,851

623,138

570,522

558,708

364,345

351,315

402,006

Capital Lease Obligations Min Short Term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-302,330
-341,545
-340,886
-449,337
-315,521
73,061
72,111
68,712
31,771
5,854
18
25,484
146,125

146,125

25,484

5,854

31,771

68,712

72,111

73,061

-315,521

-449,337

-340,886

-341,545

-302,330

Long-term Liabilities Other

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
69,408
68,459
93,506
44,112
6,437
7,036
7,598
13,238
22,032
22,925
11,825
12,302

12,302

11,825

22,925

22,032

13,238

7,598

7,036

6,437

44,112

93,506

68,459

69,408

Deferred Long Term Liability

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
140,103
183,662
235,836
282,143
327,755
372,981
414,059
501,529
647,600
796,149
967,297
1,120,985
0

1,120,985

967,297

796,149

647,600

501,529

414,059

372,981

327,755

282,143

235,836

183,662

140,103

> Total Stockholder Equity

7,746
13,245
29,288
38,381
53,727
44,815
50,110
91,953
91,274
91,274
83,253
91,036
79,560
79,941
83,447
93,016
87,937
90,839
97,089
96,121
95,976
99,540
119,858
189,460
176,834
153,454
196,421
688,053
708,993
667,279
709,077
1,051,302
1,105,404
1,181,850
1,389,902
2,050,207
2,155,494
2,347,810
2,655,308
3,380,506
3,681,875
3,990,315
4,245,571
5,293,621

5,293,621

4,245,571

3,990,315

3,681,875

3,380,506

2,655,308

2,347,810

2,155,494

2,050,207

1,389,902

1,181,850

1,105,404

1,051,302

709,077

667,279

708,993

688,053

196,421

153,454

176,834

189,460

119,858

99,540

95,976

96,121

97,089

90,839

87,937

93,016

83,447

79,941

79,560

91,036

83,253

91,274

91,953

50,110

44,815

53,727

38,381

29,288

13,245

7,746

Common Stock

133
2,822
2,822
3,642
3,642
27,254
27,254
27,254
66,584
66,584
66,584
27,254
27,254
66,584
27,254
27,254
27,254
27,254
27,254
27,254
27,254
27,254
27,254
27,254
66,584
66,584
66,584
80,752
80,752
80,752
80,752
80,751
80,751
80,751
80,751
80,751
80,751
80,751
80,751
80,751
80,751
80,751
80,751
0

80,751

80,752

66,584

27,254

66,584

27,254

66,584

27,254

3,642

2,822

133

Retained Earnings

7,429
10,423
10,966
12,265
14,519
17,561
22,856
25,369
24,690
24,690
16,669
24,452
12,975
13,356
16,863
26,432
21,352
24,255
30,504
29,537
29,392
32,956
53,273
122,876
110,250
86,870
103,289
115,573
135,917
83,834
89,372
-71,520
-338,266
-368,480
-388,342
6,420
-12,206
36,813
172,675
494,981
459,822
545,360
518,403
591,464

591,464

518,403

545,360

459,822

494,981

172,675

36,813

-12,206

6,420

-388,342

-368,480

-338,266

-71,520

89,372

83,834

135,917

115,573

103,289

86,870

110,250

122,876

53,273

32,956

29,392

29,537

30,504

24,255

21,352

26,432

16,863

13,356

12,975

24,452

16,669

24,690

25,369

22,856

17,561

14,519

12,265

10,966

10,423

7,429

Capital Surplus

Treasury Stock

Other Stockholders Equity

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
316,146
361,582
373,046
463,986
846,328
883,139
961,737
1,036,270
1,284,478
1,424,085
1,458,905
1,564,253
0

1,564,253

1,458,905

1,424,085

1,284,478

1,036,270

961,737

883,139

846,328

463,986

373,046

361,582

316,146

Common Stock Shares Outstanding	80,751
Net Invested Capital	8,269,258
Net Working Capital	6,108,678

	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Begin Period Cash Flow	796,927	297,966	771,623	798,087	-	-	-	-	-	-	-	-	-	-	-
Capital Expenditures	5,928,165	371,950	378,661	243,830	76,684	10,838	7,102	8,159	12,107	9,365	15,904	1,576	2,220	7,415	12,202
Change In Cash	6,822,457	241,629	-752,528	-456,094	760,274	6,932	10,834	-	-	-	-	-	-	-	-
Change In Working Capital	1,712,609	-997,803	-181,488	17,951	-69,582	-	-	-	-	-	-	-	-	-	-
Change To Account Receivables	-	-954,419	-1,629,230	-160,558	-80,470	-236,004	-69,946	-	-	-	-	-	-	-	-
Change To Inventory	-1,576,566	-389,811	-160,337	-100,509	-111,764	-49,025	-54,272	-	-	-	-	-	-	-	-
Change To Liabilities	-	468,871	1,173,389	603,816	174,499	95,280	85,022	-	-	-	-	-	-	-	-
Change To Netincome	-	287,432	97,526	80,786	29,576	58,731	7,268	-	-	-	-	-	-	-	-
Change To Operating Activities	-	-72,295	210,097	-367,655	10,686	22,896	-6,760	-	-	-	-	-	-	-	-
Depreciation	345,597	128,866	186,309	81,784	51,379	7,755	6,311	-	-	-	-	-	-	-	-
Dividends Paid	-59,867	-	-	-21,088	-40,073	-1,457	-1,457	-	-1,581	-1,028	-1,175	-2,540	-824	-	-
End Period Cash Flow	7,359,947	539,595	218,866	501,599	798,087	-	-	-	-	-	-	-	-	-	-
Free Cash Flow	-2,194,195	-716,662	-360,734	-371,556	-42,875	-	-	-	-	-	-	-	-	-	-
Investments	-6,045,018	-65,995	661	127,762	-11,986	-23,627	442	-	-	-	-	-	-	-	-
Net Borrowings	-	1,127,467	30,394	47,080	135,806	58,517	44,207	-	-	-	-	-	-	-	-
Net Income	591,464	486,241	158,525	-331,670	48,714	94,795	5,826	-	-	-	-	-	-	-	-
Other Non Cash Items	14,334	-110,090	-79,975	45,558	10,484	-	-	-	-	-	-	-	-	-	-
Total Cash From Financing Activities	-	1,127,467	30,394	25,992	869,666	57,060	44,207	26,149	69,259	2,850	3,923	19,119	15,263	3,619	15
Total Cash From Operating Activities	3,733,970	-108,511	121,017	-182,164	11,175	-3,671	-25,424	-	-	3,511	8,297	1,252	-	6,731	12,865
Total Cashflows From Investing Activities	-	-705,563	-676,780	-260,009	-120,567	-46,457	-7,950	-	-	-	-	-	-	-	-

	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2008-09-30	2007-09-30	2006-09-30
Begin Period Cash Flow	1,635,182	502,680	566,668	609,488	315,168	502,061	311,976	235,937	354,353	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capital Expenditures	4,993,939	297,892	865,683	118,968	341,036	7,813	15,588	7,513	89,720	79,174	136,898	82,090	112,952	271,456	11,627	3,435	48,091	20,409	16,715	10,916	10,838	7,182	3,387	1,852	7,102	3,519	3,088	573	8,159	6,282	4,646	1,191	6,825	6,194	0	0	12,107	9,365	15,904	1,576	895	2,221	7,415	12,202
Change In Cash	5,708,183	854,457	133,088	-42,819	194,110	-205,925	177,404	76,039	-216,433	65,809	-81,852	-164,291	-333,421	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change In Working Capital	709,123	1,294,590	-709,303	419,463	-206,497	-851,498	-105,394	165,586	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change To Account Receivables	-	349,512	-784,174	1,203,175	-775,328	-503,999	211,112	113,795	-721,598	-343,561	-109,560	-22,005	219,973	-	-	-	6,851	107,398	169,128	169,657	-	-	-	6,198	-	15,467	4,297	12,842	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change To Inventory	2,414,867	-2,622,339	-824,132	-568,113	120,671	-387,285	-224,079	100,882	-96,979	-78,043	42,962	14,286	18,886	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change To Liabilities	-	2,477,460	989,599	347,451	184,353	188,278	69,456	26,783	409,550	406,347	36,542	9,455	-122,907	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change To Netincome	-	-60,674	243,559	32,175	114,765	84,215	97,144	-8,693	20,538	-8,371	54,513	4,957	-29,748	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change To Operating Activities	-	994,476	-21,663	-422,422	337,801	-204,539	-143,988	-61,569	121,357	18,608	36,442	-22,084	-193,132	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation	193,758	48,849	38,650	31,919	48,070	30,640	26,357	23,800	59,080	32,803	19,459	14,370	30,031	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-5,546	-4,614	-49,707	-49,707	-49,707	-49,707	-	-	-	-	-	-	-3,534	-10,174	-10,174	-	-23,699	-50,246	-49,015	-23,256	-1,457	-1,457	-1,457	-	-	-	-	-	-	-	-	-	-1,024	-1,024	-	-	-1,581	-1,028	-1,175	-2,540	-	-824	-	-
End Period Cash Flow	7,359,947	1,635,182	502,680	566,668	539,595	315,168	502,061	311,976	218,866	354,353	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow	-2,605,775	865,396	-652,389	198,573	-155,718	-684,288	14,797	108,548	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Investments	-4,335,965	-637,734	35,219	-132,508	8,641	-5,410	-78,460	9,235	16,196	-89,792	-140,633	-126,393	8,124	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Borrowings	-	258,325	1,263,343	-45,561	397,737	502,143	253,737	-26,149	-96,311	105,014	-15,622	29,245	-156,828	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	696,655	-77,582	82,537	-110,147	321,416	133,044	51,935	-20,155	172,360	26,167	1,944	-68,411	-199,578	5,538	-	20,344	10,036	17,651	2,379	10,630	69,602	20,318	5,020	-	1,754	6,250	2,902	-	9,569	-	381	-	7,783	-	172	172	-	-	-	-	-	-	-	-
Other Cashflows From Financing Activities	-	-	-	-	-	-	-	-	-	-	-	-	-3,534	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Cashflows From Investing Activities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	91	-	-	-	-	-	93	-	-	-	-	-	-	-	-	-	-	6,875	-	-	-	-	-	-	-	-	-	-	-
Other Non Cash Items	269,668	-	-	-44,317	-55,782	-37,632	1,994	-18,670	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Cash From Financing Activities	-	253,711	1,213,637	-45,561	397,737	502,143	253,737	-26,149	-96,311	105,014	-15,622	29,245	-160,363	177,259	91,296	45,543	568,024	-	-	-	57,060	48,994	5,472	-	44,207	-	-	-	26,149	17,114	9,305	4,354	34,341	30,772	-	-	69,259	2,850	3,923	19,119	30,484	15,263	3,619	15
Total Cash From Operating Activities	2,388,164	1,357,274	-343,284	394,990	274,086	-605,135	59,915	162,622	31,043	50,588	74,404	-67,143	-265,188	146,771	-	-	24,463	71,989	130,679	82,772	-	-	27,206	16,242	-	11,155	12,983	9,369	-	-	-	-	-	-	-	-	-	3,511	8,297	1,252	-	-	6,731	12,865
Total Cashflows From Investing Activities	-	-432,095	-936,653	-324,775	-450,207	-85,667	-124,743	-44,945	-140,300	-89,792	-140,633	-126,393	92,130	-	-	8,177	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,471	-	-	-	-	-	-	-	-	-	-	-

	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cost Of Revenue	11,686,598	3,169,083	2,004,100	1,012,091	463,523	388,999	199,715	171,817	135,742	131,896	94,033	65,548	81,740	46,217	46,807	38,595
Ebit	-	1,487,497	1,062,795	172,832	196,333	239,142	93,044	-	-	-	-	-	-	-	-	-
Ebitda	2,507,899	1,206,431	488,633	-88,563	128,747	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	4,929,078	3,012,255	1,891,015	804,907	518,693	466,983	246,699	-	-	-	-	-	-	-	-	-
Income Before Tax	1,417,446	757,698	210,258	-209,198	68,075	150,395	13,433	7,478	5,469	12,111	10,748	7,106	8,040	2,647	9,025	4,195
Income Tax Expense	-	271,750	115,296	24,094	55,815	55,600	7,607	5,498	5,363	8,017	4,433	2,893	3,234	1,280	3,526	1,690
Interest Expense	744,857	279,713	141,324	67,470	42,961	-37,982	-32,218	26,230	18,589	21,898	7,446	5,025	2,131	1,219	625	829
Interest Income	-	-	-	-	6,614	-	-	-	-	-	-	-	-	-	-	-
Minority Interest	-9,968	65,949	67,734	91,728	0	0	0	-	-	-	-	-	-	-	-	-
Net Income	591,464	486,241	116,442	-215,604	40,756	94,795	5,826	-	-	-	-	-	-	-	-	-
Net Income Applicable To Common Shares	-	486,241	158,525	-331,670	48,714	94,795	5,826	-	-	-	-	-	-	-	-	-
Net Income From Continuing Ops	601,432	485,948	125,569	-224,860	40,696	94,795	5,826	-	-	-	-	-	-	-	-	-
Net Interest Income	-744,857	-279,914	-141,337	-72,060	-39,959	-	-	-	-	-	-	-	-	-	-	-
Operating Income	2,322,577	1,512,569	796,509	129,090	170,453	239,142	93,044	50,021	37,714	29,357	18,195	12,131	12,341	2,190	10,445	2,339
Other Operating Expenses	-	99,874	99,874	99,874	99,874	13,601	13,601	-	-	-	-	-	-	-	-	-
Reconciled Depreciation	345,597	169,020	137,050	53,165	17,711	-	-	-	-	-	-	-	-	-	-	-
Research Development	-	-	-	-	-	-	-	-	-	731	793	-	102	60	1,905	-
Selling General Administrative	951,099	464,062	368,370	222,257	103,408	214,239	153,655	103,896	96,363	81,355	49,471	34,685	26,013	20,640	16,739	13,232
Tax Provision	816,014	271,750	84,689	15,662	27,379	-	-	-	-	-	-	-	-	-	-	-
Total Operating Expenses	14,293,099	4,668,769	3,098,605	1,687,908	811,764	616,839	353,370	-	-	-	-	-	-	-	-	-
Total Other Income Expense Net	-	-	-570,400	-316,959	-91,804	-88,747	-79,611	-	-	-	-	-	-	-	-	-
Total Revenue	16,615,676	6,181,338	3,895,115	1,816,998	982,217	855,982	446,414	341,740	259,750	249,013	166,233	111,810	122,159	69,725	77,186	55,060

	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31
Cost Of Revenue	5,711,949	4,160,163	983,685	609,876	1,443,521	624,804	493,324	502,174	836,865	437,464	327,678	293,184	481,972	253,415	149,290	129,116	126,154	116,407	115,584	91,430	158,782	86,540	78,506	54,888	56,312	45,549	48,400	42,096	56,344	41,911	39,767	34,821	24,844	36,715	36,262	36,262
Ebit	-	229,575	550,485	276,796	682,756	380,278	240,653	56,409	375,107	90,845	63,173	-35,814	-37,155	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Ebitda	1,571,670	261,979	547,035	55,478	610,031	336,875	187,601	56,409	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	2,273,488	818,783	942,150	665,719	1,196,847	711,132	516,357	483,417	846,193	539,941	263,504	169,225	239,255	233,645	166,542	163,763	168,972	136,638	126,130	100,901	202,005	106,482	87,462	81,317	101,840	62,337	53,486	36,394	57,222	42,782	38,763	30,131	43,452	24,223	29,823	29,823
Income Before Tax	1,081,686	24,690	357,473	-65,637	432,405	221,844	113,843	-16,844	221,399	35,189	27,000	-62,266	-195,057	12,203	-	34,460	17,049	28,652	4,970	17,404	108,736	32,183	8,869	607	3,096	10,812	5,818	-	15,993	-	1,579	-	13,294	-	800	800
Income Tax Expense	-	94,062	298,846	41,734	108,425	89,573	71,691	2,061	46,714	8,564	21,885	7,526	21,318	-	-	14,199	7,014	11,001	2,591	6,774	39,134	11,866	3,849	752	1,343	4,562	2,916	-	6,425	-	1,198	-	5,512	-	628	628
Interest Expense	296,226	183,328	134,310	78,489	112,058	73,432	41,153	44,005	83,290	22,852	16,714	12,082	-53,560	11,038	21,394	9,480	11,489	7,031	8,776	15,665	14,808	9,798	6,170	9,276	6,905	6,409	6,845	9,620	8,456	6,939	8,501	2,395	101	10,022	4,233	4,233
Minority Interest	-3,658	-8,209	74,939	72,342	65,949	55,612	53,311	53,854	49,753	47,312	35,111	30,847	59,629	7,032	593	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	696,655	-77,582	84,882	-99,274	321,416	133,044	49,675	-19,127	172,360	26,167	1,944	-68,411	-199,578	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income Applicable To Common Shares	-	-77,582	82,537	-110,147	321,416	133,044	51,935	-20,155	172,360	26,167	-7,171	-74,914	-199,578	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income From Continuing Ops	700,314	-69,373	87,557	-103,251	323,980	132,271	47,396	-18,800	174,686	26,625	8,381	-69,139	-216,375	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Interest Income	-296,060	-183,374	-134,355	-78,548	-112,170	-73,451	-41,175	-44,046	-83,290	-22,851	-16,714	-13,325	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	1,269,720	232,755	473,124	230,680	691,694	388,685	214,985	176,963	464,855	287,157	46,404	-8,824	-37,155	61,252	33,538	50,113	55,234	47,060	36,117	21,759	134,357	46,261	24,223	34,301	60,388	15,080	14,044	3,531	25,985	14,061	8,606	1,369	17,720	-	-	-
Other Operating Expenses	-	42,930	39,269	16,186	41,577	22,104	20,112	16,081	30,248	12,353	11,986	9,513	13,404	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reconciled Depreciation	193,758	53,961	55,252	42,625	65,568	41,598	32,606	29,248	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Selling General Administrative	362,398	212,612	178,620	149,183	139,191	97,398	101,631	104,074	123,333	92,432	217,100	52,410	263,006	158,203	124,044	103,387	102,772	82,968	83,300	72,791	62,554	54,340	61,465	45,408	37,576	42,552	34,589	29,067	26,292	22,869	27,732	27,003	23,591	23,287	24,742	24,742
Tax Provision	381,372	94,062	269,916	37,614	108,425	89,573	66,447	1,955	46,714	8,564	18,619	6,873	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Operating Expenses	6,715,717	4,746,190	1,452,711	1,044,916	1,948,674	947,251	794,696	808,627	1,218,203	690,247	544,778	471,233	758,382	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Other Income Expense Net	-	-	-	-	-	-	-	-	-238,507	-250,488	-28,443	-52,963	-157,902	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Revenue	7,985,437	4,978,946	1,925,835	1,275,596	2,640,368	1,335,936	1,009,681	985,590	1,683,058	977,405	591,181	462,409	721,227	487,060	315,832	292,879	295,126	253,045	241,714	192,331	360,787	193,022	165,968	136,205	158,152	107,886	101,886	78,490	113,566	84,693	78,530	64,952	68,295	60,938	66,085	66,085

Gross Profit (+$)
totalRevenue	16,615,676
Cost of Revenue	-11,686,598
Gross Profit	4,929,078	4,929,078

Operating Income (+$)
Gross Profit	4,929,078
Operating Expense	-14,293,099
Operating Income	2,322,577	-9,364,021

Operating Expense (+$)
Research Development	-
Selling General Administrative	951,099
Selling And Marketing Expenses	-
Operating Expense	14,293,099	951,099

Net Interest Income (+$)
Interest Income	-
Interest Expense	-744,857
Net Interest Income	-744,857	-744,857

Pretax Income (+$)
Operating Income	2,322,577
Net Interest Income	-744,857
Other Non-Operating Income Expenses	-
Income Before Tax (EBT)	1,417,446	2,322,577 EBIT - interestExpense = -744,857 591,464 1,336,321
Interest Expense	744,857
Earnings Before Interest and Taxes (ebit)	-	2,162,302
Earnings Before Interest and Taxes (ebitda)	2,507,899

After tax Income (+$)
Income Before Tax	1,417,446
Tax Provision	-816,014
Net Income From Continuing Ops	601,432	601,432
Net Income	591,464
Net Income Applicable To Common Shares	-

Non-recurring Events
Discontinued Operations	-
Extraordinary Items	-
Effect of Accounting Charges	-
Other Items	-
Non Recurring	-
Other Operating Expenses	-
Total Other Income/Expenses Net	-	744,857

1. Financial Health

2. Market Valuation

3. Summary

Extra: full reports

Community

Laboratorios Richmond S.A.C.I.F Buy or Sell?

1.1. Profitability of Laboratorios Richmond S.A.C.I.F.

1.1.1. Net Profit Margin of Laboratorios Richmond S.A.C.I.F.

1.1.2. Return On Assets of Laboratorios Richmond S.A.C.I.F.

1.1.3. Return On Equity of Laboratorios Richmond S.A.C.I.F.

1.2. Operating Efficiency of Laboratorios Richmond S.A.C.I.F.

1.2.1. Operating Margin of Laboratorios Richmond S.A.C.I.F.

1.2.2. Operating Ratio of Laboratorios Richmond S.A.C.I.F.

1.3. Liquidity of Laboratorios Richmond S.A.C.I.F.

1.3.1. Current Ratio of Laboratorios Richmond S.A.C.I.F.

1.3.2. Quick Ratio of Laboratorios Richmond S.A.C.I.F.

1.4. Solvency of Laboratorios Richmond S.A.C.I.F.

1.4.1. Total-Debt-to-Total-Assets Ratio of Laboratorios Richmond S.A.C.I.F.

1.4.2. Debt-To-Equity Ratio of Laboratorios Richmond S.A.C.I.F.

2. Market Valuation of Laboratorios Richmond S.A.C.I.F.

2.1. Price-to-Earnings Ratio of Laboratorios Richmond S.A.C.I.F.

2.2. Price/Earnings-to-Growth Ratio of Laboratorios Richmond S.A.C.I.F.

2.3. Price-to-Book Ratio of Laboratorios Richmond S.A.C.I.F.

3.1. Key Performance Indicators

3.2. Fundamental Score

Penke's Stock Scanner

Create your own Stock Scanner

3.3. Technical Score

Penke's Symbol Scanner

Create your own Symbol Scanner

Latest Balance Sheet

Summary

Assets

Total Current Assets

Long-term Assets

Liabilities & Shareholders' Equity

Total Current Liabilities

Long-term Liabilities

Total Stockholder Equity

Other

Balance Sheet

Cash Flow

Income Statement

Latest Income Statement (annual, 2021-12-31)

Stay informed with my latest content.

Comments

Leave a comment

Penke's Market Notifications

GBPRUB.FOREX

CADRUB.FOREX

SGDBRL.FOREX

HKDRUB.FOREX

CHFCZK.FOREX

Laboratorios Richmond S.A.C.I.F
Buy or Sell?